Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 186pembrolizumab 151Magnetic Resonance Spectroscopy 151Carboplatin 114Biopsy 104Cyclophosphamide 96Cisplatin 88Paclitaxel 79Gemcitabine 71Bevacizumab 68fludarabine 60Nivolumab 58Fluorouracil 51Radiotherapy 49Dexamethasone 47Capecitabine 47Pemetrexed 46Oxaliplatin 44Docetaxel 44Rituximab 43Leucovorin 41Doxorubicin 40venetoclax 39durvalumab 39atezolizumab 39Temozolomide 32Standard of Care 32Radiation 32Cetuximab 32130-nm albumin-bound paclitaxel 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × methoxyamine × 30 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡